Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19.
Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19.
Antimicrob Agents Chemother. 2020 Aug 31;:
Authors: Lê MP, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit JF, Peytavin G
Abstract
Remdesivir has reported efficacy against SARS-CoV-2 in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In ICU settings, in which multiple organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and SEBCD. Additional studies may prove informative, particularly in the evaluations of therapeutic options for COVID-19.
PMID: 32868327 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Lê MP, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit JF, Peytavin G Tags: Antimicrob Agents Chemother Source Type: research
More News: Chemotherapy | COVID-19 | Dialysis | Hemodialysis | Lung Transplant | Microbiology | SARS | Study | Transplant Surgery | Transplants